Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief ...

For PSP, they are AADvac1, AZP2006, and a drug to be announced. For CBS, no official word, but the drug is likely BIIB080. Industry representatives from 52 companies joined. “That was great to see,” ...

Biogen’s tau antisense Biogen also reported preliminary data at CTAD from a phase 1b study of BIIB080, an antisense drug targeting tau, in 46 mild Alzheimer’s patients. There were ...

Under Dr. Geary's leadership, Ionis submitted over 50 investigational new drug applications to regulatory agencies and ...

That same month, the FDA granted fast track designation to Biogen's investigational tau-targeting therapy BIIB080 for the treatment of Alzheimer's. Biogen's earnings report for Q1 shows that first ...

Results of the first-in-human, randomized, double-blind, placebo-controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau ...

and hear about exciting investment opportunities.

That same month, the FDA granted fast track designation to Biogen's investigational tau-targeting therapy BIIB080 for the treatment of Alzheimer's.